Pooled Placebo

BIOLOGICAL2 trials

Sponsors

Quince Therapeutics S.p.A., Alladapt Immunotherapeutics, Inc.

Conditions

Food AllergyGenetic SyndromeNervous System Disease

Phase 1

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

CompletedNCT04856865

Alladapt Immunotherapeutics, Inc.Food Allergy

Start: 2021-04-20End: 2022-12-13Updated: 2024-05-16

Phase 3

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

CompletedNCT02770807

Quince Therapeutics S.p.A.Genetic Syndrome, Nervous System Disease

Start: 2017-03-02End: 2021-05-13Updated: 2024-05-10

Related Papers

Long-term safety of dexamethasone sodium phosphate encapsulated in autologous erythrocytes in pediatric patients with ataxia telangiectasia

Frontiers in Neurology2025-01-236 citations

ADP101 multifood oral immunotherapy for food-allergic patients: Harmony phase 1/2 randomized clinical trial.

2024-12-10

Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.

2024-09-0115 citations